共 23 条
[1]
Pharmacokinetics of a microemulsion formulation of cyclosporine in pediatric liver transplant recipients. Cooney G F, Lum B L, Meligeni J A, et al. Transplantation Proceedings . 1996
[2]
Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Cantarovich M, Besner J G, Barkun J S, et al. Clinical Transplantation . 1998
[3]
Transplantation[P]. 英国专利:GB9904281D0,1999-04-21
[4]
Transplantation[P]. 英国专利:GB9904281D0,1999-04-21
[5]
Neoral absorption profiling: an evolution in effectiveness. Belitsky P, Levy G A, Johnston A. Transplantation Proceedings . 2000
[6]
Low exposure to cyclosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation. Citterio F, Torricelli P, Serino F, et al. Transplantation Proceedings . 1998
[7]
Improved graft survival after renal transplantation in the United States, 1988 to 1996. Hariharan S, Johnson C P, Bresbnahan B A, et al. The New England Journal of Medicine . 2000
[8]
Conversion to C2 cyclosporine monitoring using Neoral immunosuppression in maintenance liver patients:improvement in renal function and hypertension. Levy G A, O’Grady C, Lilly L, et al. Joint meeting of the AST/ASTS, May 2001, Chicago. Abstract .
[9]
Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period. Amante A J, Kahan B D. Transplantation Proceedings . 1996
[10]
JohnstonA. Newstrategiesfortherapeuticdrugmonitor ingofNeoral . 1998